

### Supplementary Table 1 Process of retrieval

---

Records search strategy	
#1	"celecoxib" or "celebrex" or "4-(5-(4-methylphenyl)-3-(trifluoro methyl)-1H-pyrazol-1-yl) benzenesulfonamide" or "SC 58635" or "SC-58635" or "SC58635"
#2	"depression" or "Depressive Symptoms" or "Depressive Symptom" or "Symptom, Depressive" or "Symptoms, Depressive" or "Emotional Depression" or "Depression, Emotional"
#3	#1 and #2

---

**Supplementary Table 2 The baseline characteristics in all included studies**

Author	Year	Diagnostic criteria	Depression type	Period of therapy	Design of experiment	Design of control	Dose of celecoxib	of depression scale	N	E(mean $\pm$ SD)	N	C(mean $\pm$ SD)
Marzieh	20	DSM-IV	Drug-naive	4 wk	Sertraline	Sertralin			14	12.4 $\pm$ 5	9	17.3 $\pm$ 5.2
Majd-1	15	-TR	Depression		plus	e plus	200 mg/day	HAMD-1				
Marzieh	20	DSM-IV		8 wk	celecoxib	placebo		7	14	7.9 $\pm$ 4	9	10.4 $\pm$ 3
Majd-2	15	-TR										
Fabiano	G. 20	SCID		1					14	9.8 $\pm$ 4.7	14	17.1 $\pm$ 7.4
Nery-1	07		Depressive or	week								
Fabiano	G. 20	SCID	mixed phases	2 wk	Celecoxi	Placebo	400 mg/day	HAMD-2	14	9.5 $\pm$ 5.7	14	12.8 $\pm$ 6.5
Nery-2	07		of bipolar		b							
Fabiano	G. 20	SCID	disorder	4 wk				1	14	10 $\pm$ 3.9	14	11.3 $\pm$ 6.2
Nery-3	07											
Fabiano	G. 20	SCID		6 wk					14	10.5 $\pm$ 3.7	14	10.6 $\pm$ 6.5
Nery-4	07											
S. Jafari-1	20	DSM-IV	Mild-to-mode	4 wk	Ab+celec	Ab+plac	400 mg/day	HAMD-1	20	14.1	20	16.65

	15	-TR	rate		oxib	ebo		7	±	± 2.13
			depression						2.27	
S. Jafari-2	20	DSM-IV		8 wk					9.6 ±	16.6 ±
	15	-TR							3.79	2.96
Payam			Mild	to					12.31	
Mohammadin	20	DSM-IV	Moderate	3 wk					±	± 2.21
ejad-1	15	-TR	Depression		Celecoxi			HAMD-1	1.78	
Payam			Among		b	Baseline	400 mg/day	7	10.42	
Mohammadin	20	DSM-IV	Breast Cancer	6 wk					±	± 2.21
ejad-2	15	-TR	Patients						1.45	
Maryam									11.9	
Alamdarsarav	20	DSM-V	Mild	to 2 wk					±	± 1.82
i-1	17		moderate						3.45	
Maryam			depression		Celecoxi			HAMD-1	9.35	
Alamdarsarav	20	DSM-V	with	4 wk	b	Placebo	400 mg/day	7	±	± 2.26
i-2	17		colorectal						2.23	
Maryam	20		cancer						7.8 ±	10.15
Alamdarsarav	17	DSM-V		6 wk					±	± 2.37

i-3

R. Musil	20 11	DSM-IV	Depression	6 wk	Celecoxi b	Placebo	400 mg/day	HAMD-1 7	18	11.8 ± 7.7	14	16.9 ± 8.6
Muhammad Ishrat	20 20	DSM-V		2 wk					66	18.2 ± 7.1	66	18.2 ± 7.2
Muhammad Ishrat	20 20	DSM-V	Bipolar depression	4 wk	Celecoxi b plus placebo	Placebo plus placebo	200 mg/day for 2 week; 400m g/day later	HAMD-1 7	66	15.7 ± 7.2	66	14.7 ± 7
Muhammad Ishrat	20 20	DSM-V		8 wk					66	14 ± 7.6	66	13.1 ± 7.2
Muhammad Ishrat	20 20	DSM-V		12 wk					66	11.7 ± 7.8	66	12.5 ± 7
Angelos Halaris-1	20 19	DSM-IV	Treatment-res istant bipolar depression	4 wk	Celecoxi b	Placebo	400 mg/day	Beck depressio n	27	8.42 ± 16.82	20	7.34 ± 17.37

Angelos	20	DSM-IV		8 wk				inventory	11.39	20	8.54 ±
Halaris-2	19							27 ±	16.66		
Bernhard	T. 20	DSM-IV		2 wk				Montgom	23.7	60	21.76
Baune-1	21								± 9.3		
Bernhard	T. 20	DSM-IV	Depression	4 wk	Vortioxet	Vortioxe	400 mg/day	ery-	22.24	60	18.7 ±
Baune-2	21				ine +	tine +		Asberg	59 ±		
					celecoxib	placebo		Depressio	10.86		
Bernhard	T. 20	DSM-IV		6 wk				n Rating	20.04	60	18.14
Baune-3	21							Scale	59 ±		
N Müller-1	20	DSM IV		1					19.8	20	20.5 ±
	06								week		
N Müller-2	20	DSM IV	Major	2 wk	Reboxeti	Reboxeti	400 mg/day	HAMD-1	15.9	20	17.3 ±
	06				ne +	ne +			7		
N Müller-3	20	DSM IV	depression	3 wk	celecoxib	placebo			13.9	17	16.4 ±
	06				± 6.5	6.9					
N Müller-4	20	DSM IV		4 wk					17 12.9	13	16.9 ±

---

	06						$\pm 7$	8.7
N Müller-5	20 06	DSM IV	5 wk		12	10.1 $\pm 6.6$	8	13.1 $\pm$ 9.3
N Müller-6	20 06	DSM IV	6 wk		10	7.9 $\pm$ 7.1	8	12.1 $\pm$ 8.3

---